Barclays PLC Acquires 48,313 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Barclays PLC raised its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 280.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,561 shares of the biotechnology company’s stock after acquiring an additional 48,313 shares during the quarter. Barclays PLC owned about 0.11% of Aldeyra Therapeutics worth $353,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. US Bancorp DE bought a new stake in shares of Aldeyra Therapeutics during the 3rd quarter valued at $30,000. Paloma Partners Management Co purchased a new stake in shares of Aldeyra Therapeutics in the third quarter worth about $62,000. The Manufacturers Life Insurance Company boosted its position in shares of Aldeyra Therapeutics by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 2,729 shares during the period. King Wealth Management Group lifted its stake in Aldeyra Therapeutics by 24.5% in the 3rd quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 2,700 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Aldeyra Therapeutics by 253.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 10,201 shares during the period. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Up 1.3 %

Aldeyra Therapeutics stock opened at $4.84 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The business has a 50-day simple moving average of $4.94 and a 200 day simple moving average of $4.98. Aldeyra Therapeutics, Inc has a 52 week low of $2.71 and a 52 week high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). As a group, sell-side analysts predict that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.